Influence of Regulatory Measures on the Rate of Spontaneous Adverse Drug Reaction Reporting in Italy
- 1 January 2008
- journal article
- Published by Springer Nature in Drug Safety
- Vol. 31 (7), 609-616
- https://doi.org/10.2165/00002018-200831070-00006
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparisonThe Lancet, 2007
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Hepatic adverse drug reactions: a case/non-case study in ItalyEuropean Journal of Clinical Pharmacology, 2006
- Evaluating Drug Effects in the Post-Vioxx WorldCirculation, 2006
- Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysisBMJ, 2005
- Drug safety and regulationBMJ, 2005
- Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention TrialNew England Journal of Medicine, 2005
- Drug-Induced AnaphylaxisDrug Safety, 2005
- Adverse Drug Reactions Related to the Use of Fluoroquinolone AntimicrobialsDrug Safety, 2003
- Increased reporting of adverse reactions to ACE inhibitors associated with limitations to drug reimbursement for angiotensin-II receptor antagonists.European Journal of Clinical Pharmacology, 2001